Replies to post #1134 on Actinium Pharmaceuticals Inc (ATNM)

[Atlanta1]

early bid now $1.22

$ATNM

[Atlanta1]

Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained

- Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016

- Iomab-B now has orphan designation in the US and EU

$ATNM

[BooDog]

Good news. Iomab-B I think will do well. Nice to see the recognition!